Dean Falb

Dean Falb has a long and varied work experience. Dean began in 1998 as the Senior Vice President of Research and Development for Praecis Pharmaceuticals (GSK). In 2002, they moved to Neogenesis (Merck) as the Vice President of Research and Development. In 2005, they joined Stryker Regenerative Medicine as the Vice President of R&D. In 2012, they became an Entrepreneur in Residence for Atlas Ventures. In 2013, they founded and became the Chief Technology Officer for Synlogic, Inc., a synthetic biology/engineered probiotic platform company focused on rare diseases, immuno-oncology and inflammatory disorders. In 2014, they became a Student Advisor for the Harvard i-lab. In 2018, they joined LogicBio Therapeutics as the Chief Scientific Officer. In 2020, they joined PlateletBio as the Chief Scientific Officer. In 2022, they became a Scientific Advisory Board Member for Novome Biotechnologies and Chief Scientific Officer for Frontera Therapeutics.

Dean Falb obtained a Ph.D. in Biochemistry and Molecular Biology from Harvard University, a B.S. in Chemistry from Purdue University, and completed an Executive Leadership Program at Harvard Business School.